Advanced searches left 3/3

Carboplatin Combination - Crossref

Summarized by Plex Scholar
Last Updated: 03 May 2022

* If you want to update the article please login/register

A Phase I Trial to Determine the Safety and Tolerability of Autophagy Inhibition Using Chloroquine or Hydroxychloroquine in Combination With Carboplatin and Gemcitabine in Patients With Advanced Solid Tumors

Autophagy may also provide survival benefits to tumor cells that are subjected to chemotherapy or radiation attack. We investigated the safety, tolerability, and effectiveness of combining CQ or HCQ with carboplatin and gemcitabine in patients with refractory solid tumors. Methods The aim of this single institution phase-escalation study was designed to determine the maximum tolerated dose of CQ/HCQ in combination with CG in patients with advanced solid tumors. In each patient dose cohort, the starting dose of CQ or HCQ 50 mg was used in conjunction with standard starting doses of CG and was increased in increments of 50 mg. The MTD was discovered in combination with CG with thrombocytopenia and/or neutropenia dose limiting, as well as CQ/HCQ 100 mg daily. Conclusion The MTD determined for CQ/HCQ was lower than previous estimates with concomitant use of chemotherapeutic therapies, owing to the myelosuppressive nature of CG in previously treated patients.

Source link: https://doi.org/10.3389/fonc.2022.811411


Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IB–IIB cervical cancer

In addition to weekly paclitaxel and carboplatin administration in neoadjuvant settings in cervical cancer stage IB–IIB, we investigated reaction rates of bevacizumab. Methods In this retrospective analysis, we included patients with FIGO 2018 stage IB–IIB cervical cancer. Based on the Response Evaluation Criteria in Solid Tumors v1. 1 criteria, the radiologic response rate was determined. One person was stage IB3, five were stage IIA, five had stage IIA, and eight were stage IIB2 patients on FIGO 2018 IB1–IB2, one had stage IB3, five had stage IIA, and 18 had stage IIB2. No such cases of Grade IV proteinuria or hypertension were reported, and no administration of bevacizumab was postponed or dose-reduced; no indication of bevacizumab was reported or dose-reduced was found. Although bevacizumab is used in the treatment of chronic cervical cancer in combination with paclitaxel and carboplatin, we did not find a correlation between bevacizumab's pathological response rate in the neoadjuvant chemotherapy setting, we did not find a trend toward superiority in the pathological response rate of bevacizumab.

Source link: https://doi.org/10.1136/ijgc-2021-002432


Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study

Carboplatin and paclitaxel are two of the most commonly used chemotherapy regimens in a variety of tumor types. Multiple malignancies have reported that selinexor, a first-in-class oral potent selective inhibitor of nuclear export Exportin-1, and CT exerts antitumor activity in multiple malignancies. DLT with grade 3 nausea and vomiting for three days was observed by one patient at 60 mg QW. In three patients, unconfirmed partial response was present in three patients; one patient was identified with esophageal, breast, and ovarian cancer. One patient with esophageal adenocarcinoma had confirmed PR, but the study was suspended due to clinical progress. Several patients with utmost blood pressure, including two patients with utr, had no prior exposure to carboplatin and/or paclitaxel. In combination with CT, the RP2D of selinexor was 60 mg QW. The combination resulted in safe clinical development with robust objective responses, which should be investigated further in tumor types for which CT is used as a measure of care.

Source link: https://doi.org/10.1007/s10637-021-01188-1


Pirfenidone Sensitizes NCI-H460 Non-Small Cell Lung Cancer Cells to Paclitaxel and to a Combination of Paclitaxel with Carboplatin

Our research examined whether pirfenidone sensitizes non-small cell lung cancer cell carcinoma cell lines to chemotherapeutic treatments. Using the sulforhodamine B assay, the cytotoxic effects of paclitaxel and pirfenidone were assessed against three NSCLC cell lines. Towards, the ability of pirfenidone to sensitize NCI-H460 cells to a mixture of paclitaxel and carboplatin was investigated. The results showed that pirfenidone sensitized NCI-H460 cells to paclitaxel treatment, reducing cell growth, viability, and proliferation, inducing changes in cell cycle profile and triggering an increase in the percentage of cell death. pirfenidone has also sensitized NCI-H460 cells to paclitaxel plus carboplatin.

Source link: https://doi.org/10.3390/ijms23073631


A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer

In recurrent ovarian cancer, NUC-1031 was combined with carboplatin in PRO-002, NUC-1031. Patients and Methods: NUC-1031 was used on days 1 and 8 with carboplatin on day 1 every 3 weeks for up to six cycles. NUC-1031 and carboplatin were investigated in a four dose cohort study. Result: A total of 25 women with recurrent ovarian cancer, a mean of 3. 8 prior lines of chemotherapy, and a median platinum-free interval of 5 months were enrolled; 15 of 25 were platinum resistant, 9 were partially platinum sensitive, and 1 was platinum sensitive. The plasma contained NUC-1031 was stable, and rapid intracellular dFdCTP levels that were unaffected by carboplatin were quickly obtained. Conclusions: In recurrent ovarian cancer, NUC-1031 combined with carboplatin is well tolerated. On days 1 and 8, with AUC5 carboplatin day 1, every three weeks for six cycles, highest efficacy was reported at the RP2CD of 500 mg/m2 NUC-1031.

Source link: https://doi.org/10.1158/1078-0432.ccr-20-4403


Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study

Purpose: This report investigated the efficacy and safety of oral PARP inhibitor veliparib, plus carboplatin, and etoposide in patients with chronic small cell lung cancer patients with treatment-nave, extensive-stage small cell lung cancer patients. Patients and Methods: Patients were randomly divided 1:1:1 to veliparib [240 mg twice daily for 14 days], veliparib plus chemotherapy, placebo followed by placebo, or placebo plus chemotherapy followed by placebo followed by placebo. With veliparib throughout the compared to placebo in SLFN11-positive patients, there was a tendency toward increased PFS. Patients in the veliparib's both, veliparib combination-only and control arms, most commonly hematologic, were diagnosed by 82%, 88%, and 68%. Conclusions: Veliparib plus platinum chemotherapy, followed by veliparib maintenance demonstrated enhanced PFS as the first-line therapy for ED-SCLC with an acceptable safety record, but there was no equivalent benefit in OS.

Source link: https://doi.org/10.1158/1078-0432.ccr-20-4259


Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors

Purpose: This phase I report evaluated the PI3K/mTORC1/2 dual inhibitor gedatolisib, tolerability, pharmacokinetics, and preliminary use of the PI3K/mTORC1/2 dual inhibitor gedatolisib, carboplatin, and paclitaxel in this phase I report. Patients with advanced solid tumors treated with 2 prior chemotherapy received intravenous gesib on days 1, 8, 15, and 22, and 22 ; carboplatin on day 8; and paclitaxel at 80 mg/m2 on days 8, 15, and 22 a day. Patients with progressive disease after cycle 6 were given a maintenance gedatolisib until progression. The recommended phase II dose is gedatolisib 110 mg on day 1, 8, 15, and 22 with carboplatin AUC5 on day 1 and paclitaxel 80 mg/m2 on days 1, 8, 15, and 22 with carboplatin AUC5 on day 1, 8, 15, and 22 on days 1, 8, 15, and 22, with carboplatin AUC5 on day 1, 8, 15, and 22 on days 1, 8, 15, and 22, as well as paclitaxel 80 mg/m2 on day 1, 8, 15, 8, 15, 20, 15, 16, tta Conclusions: Gedatolisib, carboplatin, and paclitaxel are tolerable, and preliminary effiicacy has been observed in CCOC.

Source link: https://doi.org/10.1158/1078-0432.ccr-21-1402


Abstract 1066: Pre-clinical combination of a PARP inhibitor, talazoparib, and carboplatin in triple-negative breast cancer

BRCA-MUT tumors account for 15-20% of triple-negative breast cancers. In NSG mice, we also used an orthotopic xenograft model of MDAMB231, which had 8-14 mice in each treatment group. Using two dosing techniques: a concomitant administration of C + T; and b T; and talazoparib first; and C three days later, each compared to vehicle control. Results: In all 7 cell lines that were PARPi PARP inhibitor-resistant, namely HCC1143, MDAMB231, and Hs578T, we found a synergistic effect of the combination of talazoplatin CI 0. 65 with the highest synergistic value. The mean 53BP1 product score climbed by 7-16 fold in combination over talazoparib alone at 0. 2 M, and the apoptotic index increased by 4-26 fold under the same conditions as above. In comparison to control P=0. 0004, sequential administration resulted in a 51% decrease in primary tumor volume in comparison to control P=0. 0004, but sequential administration resulted in a 69. 2% primary tumor volume inhibition P 0. 0001. P=0. 0003>3. The talazoparib first combination therapy resulted in a 59% decrease in lung micrometastasis P=0. 0003. When mixed with carboplatin, we observed increased DNA damage and cell death amongst PARPi-resistant cell lines and cells in lower amounts of talazoparib.

Source link: https://doi.org/10.1158/1538-7445.am2021-1066


Abstract CT109: Phase I study of mTORC1-2 inhibitor sapanisertib (TAK-228) in combination with carboplatin plus paclitaxelin patients with advanced solid malignancies and mTOR pathway alterations

Abstract: The addition of the mTORC1/2 inhibitor sapanisertib improves sensitivity to platinum chemotherapy and dramatically raises cancer cell death in paclitaxel-induced cancer cells in pre-clinical studies. Carboplatin plus paclitaxel is an effective treatment for a variety of cancers, including non-small cell lung cancer, ovarian cancer, and others. In patients with advanced solid malignancies enriched with mTOR pathway alterations, this phase 1 research investigated sapanisertib's safety and tolerability in conjunction with carboplatin plus paclitaxel. No DLTs were found among the 12 patients treated with Dose levels 1-3, 11 patients were evaluable for dose-limiting toxicities and no DLTs were found. One patient had a DLT, while 7 patients were treated in Dose level 4 and six others that were evaluable for DLTs, one patient had a DLT. Of 17 patients evaluable for response, disease control was 76. 4 percent, with two patients who had partial responses. Responders were a patient with sarcomatoid renal cell carcinoma displaying EWSR1-POU5F1 fusion, who has been on therapy for more than 18 months. In addition, a patient with castrate resistant prostate cancer who progressed on cabazitaxel died of PTEN failure but remains on therapy for 7. 3 months. Conclusion: Sapanisertib in combination with carboplatin plus paclitaxel established a manageable safety profile, with preliminary antitumor activity found in patients with advanced malignancies harboring mTOR pathway mutations. Phase I of mTORC1 inhibitor sapanisertib in combination with carboplatin plus paclitaxelin patients with advanced solid malignancies and mTOR pathway changes [abstract].

Source link: https://doi.org/10.1158/1538-7445.am2021-ct109


Neoadjuvant Pertuzumab plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2 Positive Breast Cancer: Real-World Data from a National Institute of Oncology in Poland.

Neoadjuvant systemic therapy has now become the gold standard in early breast cancer management. Patients with HER2-positive breast cancer can have a pathologic complete response when combined with trastuzumab +/- pertuzumab targeted therapy. We explored the causes that contributed to the development of pCR and presented the adverse effects of the targeted therapies, which opened a discussion about optimizing the therapy of elderly women with HER-2 positive breast cancer.

Source link: https://doi.org/10.20944/preprints202201.0164.v1

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions